GLP-1 drugs show early promise for treating substance use disorders, but evidence remains preliminary

GLP-1 receptor agonists (like semaglutide and tirzepatide), already transformative for obesity and diabetes, are being investigated as a potential treatment for substance use disorders. Growing preclinical, observational, and early clinical data suggest these drugs may reduce cra